| Type | Title | Date Released | |
|---|---|---|---|
6-K | PolyPid Expands Pipeline with PD01B for Diabetic Foot Infections and Highlights D-PLEX₁₀₀ Milestones | ||
6-K | European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀ | ||
6-K | PolyPid Regains European Commercialization Rights for D-PLEX100 from ADVANZ PHARMA | ||
SCHEDULE 13G/A | Centaurus Investments Ltd (Filed by) | ||
6-K | PolyPid Ltd. Reports Second Quarter 2026 Financial Results and Provides Regulatory Update | ||
S-8 | Form S-8 | ||
SCHEDULE 13G/A | Rosalind Advisors, Inc. (Filed by) | ||
6-K | PolyPid Reports Second Quarter 2026 Financial Results and Provides Corporate Update on D-PLEX₁₀₀ | ||
6-K | PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX 100 | ||
6-K | PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada | ||
4 | Warshavsky Ori (Reporting) | ||
4 | Missulawin Jonathan (Reporting) |
